{"id":225526,"date":"2026-02-26T12:33:30","date_gmt":"2026-02-26T09:33:30","guid":{"rendered":"https:\/\/new-inbit.dev-praxis.gr\/?post_type=hta_library&#038;p=225526"},"modified":"2026-02-26T12:33:31","modified_gmt":"2026-02-26T09:33:31","slug":"insulin-pump-therapy-for-type-1-diabetes","status":"publish","type":"hta_library","link":"https:\/\/www.inbit.gr\/el\/hta_library\/insulin-pump-therapy-for-type-1-diabetes\/","title":{"rendered":"Insulin pump therapy for type 1 diabetes"},"content":{"rendered":"\n<p>The Alberta Health and Wellness\u2019 Executive Committee accepted the Alberta Health Technology&nbsp;Decision Program\u2019s Advisory Committee\u2019s recommendation to undertake a STE analysis of insulin&nbsp;delivery systems. The purpose of this report is to address the following questions of interest:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>What is the potential role of insulin pump therapy (IPT) in the intensive treatment of\u00a0Albertans with type 1 diabetes mellitus (T1DM) compared to multiple daily injections\u00a0(MDI)?<\/li>\n\n\n\n<li>What subpopulation(s) would benefit from IPT compared with MDI (syringe and pen)?<\/li>\n\n\n\n<li>What are the established criteria for initiating IPT?<\/li>\n\n\n\n<li>What are the economic considerations for IPT compared with MDI?<\/li>\n<\/ul>\n\n\n\n<p>T1DM, characterized by high blood glucose levels that require lifelong insulin therapy, can cause&nbsp;short- and long-term complications in different organs such as the heart, eyes, kidneys, and blood&nbsp;vessels. It may cause neuro-cognitive dysfunction and behavioural changes in children. In pregnant&nbsp;women high glucose levels are associated with increased risk of fetal congenital malformation, perinatal&nbsp;mortality, obstetric complications, and neonatal morbidity.<\/p>\n\n\n\n<p>Although T1DM usually accounts for only a minority of the total burden of diabetes in a population&nbsp;(approximately 10%), it is the most predominant form of the disease in younger age groups in most&nbsp;developed countries. It can develop at any age but usually appears in childhood or adolescence.&nbsp;Males and females tend to be equally vulnerable.<\/p>\n\n\n\n<p>Over 240,000 Canadians live with T1DM. In 2007 the estimated number of prevalent cases of&nbsp;T1DM among Canadian youth (0 to 14 years) was 8400. The incidence rate for this age group was&nbsp;estimated at 21.7 per 100,000 cases in 2007. The estimated incidence rate increases with age from&nbsp;14.7 for 0- to 4-year-olds, to 24.0 for 5- to 9-year-olds, and 26.3 for 10- to 14-year-olds.<\/p>\n\n\n\n<p>Intensive management of T1DM delivered by MDI is the accepted standard of care for achieving&nbsp;and maintaining near-normal blood glucose in order to reduce the risk of complications. Despite&nbsp;recent advances in intensive insulin therapy, fear of inducing hypoglycemia remains a major barrier&nbsp;in achieving optimal glycemic control safely in all age groups. Guidelines for intensive insulin&nbsp;therapy of T1DM recommend an individualized, intensive insulin regimen using either MDI or IPT.&nbsp;IPT is usually considered after MDI has been tried but has failed to optimize glycemic control safely.<\/p>\n\n\n\n<p>An insulin pump is a complex computerized electronic device used for continuous subcutaneous&nbsp;insulin infusion. IPT consists of a basal-bolus injection; i.e., continuous infusion of low-dose rapidacting&nbsp;insulin analogues (such as insulin lispro or insulin aspart) and pre-meal bolus injections of&nbsp;rapid-acting insulin analogues. There are three main insulin pump manufacturers whose pumps are&nbsp;available on the Canadian market with licence approval from Health Canada: Animas Canada,&nbsp;Disetronic Medical Systems, and Medtronic of Canada.<\/p>\n\n\n\n<p>Both MDI and IPT are available in Alberta and, according to Alberta experts, most individuals with&nbsp;T1DM are MDI users (approximately 12% of youth and 13% of adults are IPT users). The key&nbsp;components of a high-quality IPT service are identifying individuals with T1DM suitable for IPT,&nbsp;ensuring appropriate composition of the specialist team (physician with a special interest in IPT, a&nbsp;diabetes nurse specialist, and a dietitian), and monitoring and supporting IPT users.<\/p>\n","protected":false},"featured_media":0,"template":"","categories":[19],"tags":[50,69],"class_list":["post-225526","hta_library","type-hta_library","status-publish","hentry","category-other","tag-diabetes","tag-insulin-pump"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.inbit.gr\/el\/wp-json\/wp\/v2\/hta_library\/225526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inbit.gr\/el\/wp-json\/wp\/v2\/hta_library"}],"about":[{"href":"https:\/\/www.inbit.gr\/el\/wp-json\/wp\/v2\/types\/hta_library"}],"wp:attachment":[{"href":"https:\/\/www.inbit.gr\/el\/wp-json\/wp\/v2\/media?parent=225526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inbit.gr\/el\/wp-json\/wp\/v2\/categories?post=225526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inbit.gr\/el\/wp-json\/wp\/v2\/tags?post=225526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}